Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies
about
TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteinsExternal control of Her2 expression and cancer cell growth by targeting a Ras-linked coactivatorInhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigenInduction of the Tat-binding protein 1 gene accompanies the disabling of oncogenic erbB receptor tyrosine kinasesErbB receptors: from oncogenes to targeted cancer therapiesEGFR/HER-targeted therapeutics in ovarian cancerStructural Insights into the Down-regulation of Overexpressed p185her2/neu Protein of Transformed Cells by the Antibody chA21Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformationNeuregulin 1-erbB2 signaling is required for the establishment of radial glia and their transformation into astrocytes in cerebral cortexConstitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasiaEndocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycinA fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptorAntibodies as therapeutic agents: vive la renaissance!Isolation of genes specifically expressed in flat revertant cells derived from activated ras-transformed NIH 3T3 cells by treatment with azatyrosineSuppression of human prostate tumor growth by a unique prostate-specific monoclonal antibody F77 targeting a glycolipid markerDifferential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes.neu protooncogene fused to an immunoglobulin heavy chain gene requires immunoglobulin light chain for cell surface expression and oncogenic transformation.Antiproliferative and apoptotic activities of ketonucleosides and keto-C-glycosides against non-small-cell lung cancer cells with intrinsic drug resistance.Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy.Disabling TNF receptor signaling by induced conformational perturbation of tryptophan-107Overexpression of ErbB2 in cancer and ErbB2-targeting strategies.HER2/neu antisense targeting of human breast carcinoma.A pretherapy biodistribution and dosimetry study of indium-111-radiolabeled trastuzumab in patients with human epidermal growth factor receptor 2-overexpressing breast cancerHER2: the neu prognostic marker for breast cancer.Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector.EGFs and ERBBs--brief history and prospectsStage- and tissue-specific expression of the neu oncogene in rat development.Testing for HER2 in Breast Cancer: A Continuing Evolution.Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake.Primary trastuzumab resistance: new tricks for an old drug.Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapyMulti-level model for the investigation of oncoantigen-driven vaccination effect.Targeting the function of the HER2 oncogene in human cancer therapeutics.Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas.HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation.Targeted tumor killing via an intracellular antibody against erbB-2.ErbB2 immune response in breast cancer patients with soluble receptor ectodomain.Comparison of prophylactic and therapeutic immunisation with an ErbB-2 (HER2) fusion protein and immunoglobulin V-gene repertoire analysis in a transgenic mouse model of spontaneous breast cancer.
P2860
Q24301604-AAD842DE-DFC4-4E40-8956-5700007CEC98Q24538358-0B57242F-CC8E-4E3D-AB01-139FCE437073Q24628627-06139BB9-5E28-4A3F-8F72-5FB6105FC522Q24651825-917EF5A0-DFCC-4B2D-9F4F-F133C0CEA5A1Q24683709-7415CB73-1229-422C-B332-07C917E57670Q26863231-054B3765-1C29-4E25-89CA-9582B98FD0E3Q27670462-22C0EB94-E490-4210-AB67-3BCE384F99B1Q28570541-1B34FBF1-1E9A-4FC4-AB33-542722007227Q28577281-C10F2A1C-BB0A-4F6C-9A65-902AFCE481EBQ28593336-344E96FA-24F0-47FC-9193-70F33D444F53Q28640044-F4B59AEC-BF8F-4A17-8B4E-5E4027BF34C7Q30839490-144F9F63-D20B-4DD3-933D-A391C530A3D9Q30992402-03D26B86-F51C-4A2E-8571-ACC88B55B3A3Q33193524-C3F72840-513E-4C43-A38C-B694948DD16BQ33216759-E0ADB3A4-A78C-4199-9488-E6735864072BQ33640235-359E8DED-B976-40D8-B394-5D8AE0E2B443Q33642507-33AAA312-05DC-4B5C-B08C-F096C392844BQ33662179-5BC4C121-2D5B-4A2B-AE4C-0331FB512FD7Q33692259-2C7E2169-1E07-49EB-901A-4CA6E95D2774Q33801908-BD3FB142-E414-4AC9-B312-60B27B6FB282Q33911557-7A5655D9-1A1D-42EF-85D8-BC99F22BDF70Q33931164-6AD40C2F-9804-4AC2-8508-C9BF577798BDQ34130563-055D8C18-1D78-4556-9184-AB7D606BE11EQ34218621-4EFA3307-55C0-46AB-9089-EC2C67035831Q34248406-D371B026-42AC-4D2F-A014-7CD5DE28D19FQ34350358-D597E9AC-C561-4031-B92E-2CD87B90A032Q34356008-CA896DFF-C0BD-4077-9FE4-6B4718C8BFA5Q34372027-50889720-5C08-4107-9B9C-2F41DF393E7FQ34424285-D5062F4D-DF12-430D-A8E8-15B77FCEFADAQ34436612-605D689D-72C2-4D02-B919-C07675F51D49Q34610251-ACF54414-5D66-41F1-84E2-31C0C191D28DQ34743875-65C82DA8-02DE-4D9F-9D8A-4A5B842DD974Q34756500-39DC6D8A-E5A3-4D1F-8994-6CA5A0C354C3Q34766486-411BF345-92DA-40A1-B611-DD91E72F33CAQ34912810-A31B8A27-1B86-48EE-A6B3-17F62CCB3D8EQ34974436-9B0F1E5E-25D6-445F-B80E-C150C3548E0FQ35054357-3B6A0B4A-59A1-4974-B4C7-D553BA3DE42BQ35769154-C79F71CA-DC78-45CE-940F-1FC1699F6343Q35809954-AA3F9B61-B791-4C8F-8487-CAC59A7177D9Q35851930-C968F502-ECB7-4773-AE96-B629F9B3A076
P2860
Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies
description
1985 nî lūn-bûn
@nan
1985 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1985 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1985年の論文
@ja
1985年論文
@yue
1985年論文
@zh-hant
1985年論文
@zh-hk
1985年論文
@zh-mo
1985年論文
@zh-tw
1985年论文
@wuu
name
Down-modulation of an oncogene ...... otype by monoclonal antibodies
@ast
Down-modulation of an oncogene ...... otype by monoclonal antibodies
@en
Down-modulation of an oncogene ...... otype by monoclonal antibodies
@nl
type
label
Down-modulation of an oncogene ...... otype by monoclonal antibodies
@ast
Down-modulation of an oncogene ...... otype by monoclonal antibodies
@en
Down-modulation of an oncogene ...... otype by monoclonal antibodies
@nl
prefLabel
Down-modulation of an oncogene ...... otype by monoclonal antibodies
@ast
Down-modulation of an oncogene ...... otype by monoclonal antibodies
@en
Down-modulation of an oncogene ...... otype by monoclonal antibodies
@nl
P2093
P1433
P1476
Down-modulation of an oncogene ...... otype by monoclonal antibodies
@en
P2093
P304
P356
10.1016/S0092-8674(85)80050-7
P407
P577
1985-07-01T00:00:00Z